Dx company Response Genetics draws huge GSK investment

Companion diagnostics continue to be all the rage. This time, Response Genetics is drawing increased attention from GlaxoSmithKline ($GSK). The drug giant already works with Response, which conducts companion diagnostic tests and other tasks for GSK's immunotherapy and cancer pipeline drug candidates, ShareCast reports. But now GSK has boosted its stake in Response, acquiring 5 million newly issued shares in the company. Story

Suggested Articles

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.

A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.